Balaxi Pharmaceuticals commenced commercial production at its new pharma plant, launching 2 products.

The company secured approvals for 29 additional products, expanding its portfolio to 31, and is progressing towards WHO-GMP certification.

Consolidated Q1 revenue was 80.68 Cr, with a net profit of 1.30 Cr.